This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate OraSure Technologies (OSUR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OraSure Technologies (OSUR) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 81.82% and 5.78%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: OraSure Technologies (OSUR) Q4 Earnings Expected to Decline
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OraSure Technologies (OSUR) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 18.18% and 2.74%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for AmerisourceBergen (ABC) in Q4 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to be driven by its core Pharmaceutical Distribution business despite a competitive industry.
What's in Store for Quidel (QDEL) This Earnings Season?
by Zacks Equity Research
Strong growth in Cardiac Immunoassay segment's revenues is likely to drive Quidel's (QDEL) top line in Q3.
Can Solid European Sales Boost Inogen (INGN) in Q3 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in the third quarter. However, the decline in rental revenues is a concern.
OraSure Technologies (OSUR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
OraSure (OSUR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Product Stocks to Trump Estimates in Q3 Earnings
by Zacks Equity Research
Here we analyze the favorable factors that are likely to boost results of medical product companies in Q3.
OraSure Technologies (OSUR) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 75.00% and 2.65%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Top Ranked Momentum Stocks to Buy for June 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 20th:
Edwards Lifesciences Pipeline Impressive, Currency Woes Stay
by Zacks Equity Research
Edwards Lifesciences (EW) rides high on product launches as well as strength in the global Transcatheter Aortic Valve Replacement market.
Quest Diagnostics to Buy Shiel to Widen Footprint in NY-NJ
by Zacks Equity Research
After the completion of Shiel's acquisition, the medical lab is expected to expand Quest Diagnostics' (DGX) physician and patient service centers network in the New York-New Jersey area.
5 Top-Ranked MedTech Growth Stocks for Solid Returns
by Zacks Equity Research
Despite the ongoing turmoil in the MedTech industry, these stocks with high growth potential can be great bets for investors.
Orthofix (OFIX) is a Great Momentum Pick for You: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, Orthofix (OFIX) stands out as one of the most suitable momentum stock.
Can OraSure (OSUR) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
OraSure (OSUR) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
by Zacks Equity Research
Why You Should Buy Stocks at Their Highs
by Tracey Ryniec
With many stocks hitting new 52-week highs, Tracey and Dave discuss the art of buying the momentum stock.
Dave's Daily Dive - Five of the Hottest Stocks on Earth
by David Bartosiak
These Zacks Rank Strong Buy stocks are breaking out to new highs on volume
Quidel (QDEL) Worth a Look: Stock Jumps 25.4% in Session
by Zacks Equity Research
Quidel Corporation (QDEL) shares jumped above 25% in the last trading session.
The Zacks Analyst Blog Highlights: CAI International, Applied Optoelectronics, OraSure Technologies, KEMET and Chemours
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CAI International, Applied Optoelectronics, OraSure Technologies, KEMET and Chemours
Why OraSure Technologies (OSUR) Could Be an Impressive Growth Stock
by Zacks Equity Research
OraSure Technologies (OSUR) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
OraSure Technologies (OSUR) Catches Eye: Stock Jumps 10.1%
by Zacks Equity Research
OraSure Technologies, Inc. (OSUR) shares jumped a little above 10% in the last trading session.
5 Top Performing Efficient Stocks to Buy Now
by Tirthankar Chakraborty
A favorable efficiency level provides impressive returns as it is positively correlated with the company's price performance
Zacks.com featured highlights: Baxter International, Lantheus Holdings, OraSure Technologies, MAM Software Group and Teradyne
by Zacks Equity Research
Zacks.com featured highlights: Baxter International, Lantheus Holdings, OraSure Technologies, MAM Software Group and Teradyne